A Trial of CRD-4730 in HFrEF

Part of paid clinical trials in Pasadena, California.

Sponsor
Cardurion Pharmaceuticals, Inc.
Study ID
NCT07750873
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • CRD-4730 — DRUG
    Experimental, Dose A, B and C
  • Placebo — DRUG
    Placebo

Study Details

CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.

Key Dates

First listed
Aug 6, 2026
Start date
Jul 15, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
525 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Study Arm 1: CRD-4730 Dose A tablet
    Participants will receive Dose A of CRD-4730 administered orally twice daily for 24 weeks
  • Experimental: Study Arm 2: CRD-4730 Dose B tablet
    Participants will receive Dose B of CRD-4730 administered orally twice daily for 24 weeks
  • Experimental: Study Arm 3: CRD-4730 Dose C tablet
    Participants will receive Dose C of CRD-4730 administered orally twice daily for 24 weeks
  • Placebo Comparator: Study Arm 4: Matched Placebo tablet
    Participants will receive placebo administered orally twice daily for 24 weeks

Primary Outcome Measure

Change from Baseline in Composite Z-Score at 24 weeks [ Time Frame: Baseline and Week 24 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Cardurion Investigative SitePasadenaCalifornia91105
Gregory Giesler
[email protected]
626-793-1227
Cardurion Investigative SiteBloomfield HillsMichigan48304
Abdul-Rahman Halabi
[email protected]
248-282-3639

Find similar trials in Pasadena, CA

By research site
Cardurion Investigative Site· Pasadena, CACardurion Investigative Site· Bloomfield Hills, MI

Related Studies